Chlamydia & Gonorrhea
Labcorp offers timely, accurate and convenient screening options that can help curb rising STI rates in the U.S.
Most recent data available from the Centers for Disease Control and Prevention showed that chlamydia and gonorrhea were on the rise for the sixth year.1 With many patients being unwilling to admit to being sexually active,2 many chlamydia and gonorrhea infections remain undiagnosed and untreated. As many as 10-20% of untreated chlamydia or gonorrhea infections progress to pelvic inflammatory disease (PID).3
OPT OUT APPROACH
Per the updated CDC guidelines, opt-out chlamydia and gonorrhea screening among young and adolescent females can increase screening, save on costs and ultimately identify more infections among patients who may not be comfortable disclosing sexual behavior.4